MA27957A1 - Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase - Google Patents

Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase

Info

Publication number
MA27957A1
MA27957A1 MA27064A MA27064A MA27957A1 MA 27957 A1 MA27957 A1 MA 27957A1 MA 27064 A MA27064 A MA 27064A MA 27064 A MA27064 A MA 27064A MA 27957 A1 MA27957 A1 MA 27957A1
Authority
MA
Morocco
Prior art keywords
quinolinone
derivative
agents
tyrosine kinase
kinase inhibitors
Prior art date
Application number
MA27064A
Other languages
English (en)
Inventor
Paul Renhowe
Sabina Pecchi
Tim Machajewski
Cynthia Shafer
Clarke Taylor
Bill Mccrea
Chris Mcbride
Elisa Jazan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MA27957A1 publication Critical patent/MA27957A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'invention concerne des composés organiques ayant les formules (I et II) dans lesquelles les variables ont les valeurs décrites dans la description. L'invention concerne également des formulations pharmaceutiques contenant les composés organiques ou leur sel pharmaceutiquement acceptable ainsi qu'un excipient pharmaceutiquement acceptable pouvant être préparées par mélange des composés organiques ou de sels pharmaceutiquement acceptables des composés organiques avec un excipient et de l'eau. L'invention concerne également une méthode de traitement d'un patient consistant à administrer une formulation pharmaceutique selon l'invention à un patient la nécessitant.
MA27064A 2000-09-11 2003-03-04 Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase MA27957A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23215900P 2000-09-11 2000-09-11

Publications (1)

Publication Number Publication Date
MA27957A1 true MA27957A1 (fr) 2006-07-03

Family

ID=22872101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27064A MA27957A1 (fr) 2000-09-11 2003-03-04 Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase

Country Status (33)

Country Link
US (6) US6605617B2 (fr)
EP (3) EP1317442B1 (fr)
JP (4) JP4361727B2 (fr)
KR (3) KR100765841B1 (fr)
CN (1) CN100351249C (fr)
AP (1) AP1666A (fr)
AT (2) ATE309996T1 (fr)
AU (2) AU2001293275B2 (fr)
BG (1) BG66087B1 (fr)
BR (2) BRPI0113757B8 (fr)
CA (1) CA2421120C (fr)
CY (2) CY1108070T1 (fr)
CZ (1) CZ304344B6 (fr)
DE (2) DE60132937T2 (fr)
DK (2) DK1317442T3 (fr)
DZ (1) DZ3425A1 (fr)
EA (1) EA006711B1 (fr)
EC (1) ECSP034548A (fr)
ES (2) ES2250480T3 (fr)
HU (1) HU230787B1 (fr)
IL (3) IL154618A0 (fr)
MA (1) MA27957A1 (fr)
MX (1) MXPA03002032A (fr)
NO (2) NO324155B1 (fr)
NZ (1) NZ524717A (fr)
OA (1) OA12428A (fr)
PL (1) PL211125B1 (fr)
PT (1) PT1650203E (fr)
SG (2) SG129306A1 (fr)
SK (1) SK287181B6 (fr)
UA (1) UA75086C2 (fr)
WO (1) WO2002022598A1 (fr)
ZA (1) ZA200301578B (fr)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
WO2003106452A2 (fr) * 2002-06-12 2003-12-24 Millennium Pharmaceuticals, Inc. Antagonistes du recepteur de l'hormone de melano-concentration
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP2573079A3 (fr) * 2002-08-23 2015-03-11 Novartis AG Dérivés de benzimidazoles quinolinones et leurs utilisations
CN100526312C (zh) * 2002-08-23 2009-08-12 诺华疫苗和诊断公司 苯并咪唑喹啉酮及其应用
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1545529A4 (fr) * 2002-09-30 2010-03-03 Bristol Myers Squibb Co Inhibiteurs de tyrosine kinase
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
WO2004069160A2 (fr) * 2003-01-28 2004-08-19 Smithkline Beecham Corporation Composes chimiques
WO2004087153A2 (fr) * 2003-03-28 2004-10-14 Chiron Corporation Utilisation de petites molecules de composes pour une immunopotentialisation
US7627675B2 (en) * 2003-05-01 2009-12-01 Cisco Technology, Inc. Methods and devices for regulating traffic on a network
CA2533626A1 (fr) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Derives de quinolinone en tant qu'inhibiteurs de c-fms kinase
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN1976706B (zh) * 2003-11-07 2012-01-18 诺华疫苗和诊断公司 抑制fgfr3及治疗多发性骨髓瘤
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
WO2005048953A2 (fr) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Derives d'amide utilises comme modulateurs de la kinase
WO2005053692A1 (fr) * 2003-12-01 2005-06-16 The Scripps Research Institute Inhibiteurs de proteines kinases a base de quinolinone perfectionnes
EP1718306A2 (fr) * 2004-02-20 2006-11-08 Chiron Corporation Modulation de processus inflammatoires et metastatiques
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
DK1845990T3 (da) * 2005-01-27 2012-01-02 Novartis Vaccines & Diagnostic Behandling af metastaserede tumorer
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
AU2006247803B2 (en) * 2005-05-13 2011-12-22 Novartis Ag Methods for treating drug resistant cancer
CA2608087C (fr) 2005-05-17 2013-12-10 Gabriel Calvin Procede de synthese de composes heterocycliques
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
EP2270000B1 (fr) 2005-05-23 2015-07-29 Novartis AG Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP2614709A1 (fr) 2005-07-18 2013-07-17 Novartis AG Petit modèle d'animal pour une réplication du VHC
BRPI0617252A2 (pt) * 2005-10-14 2011-07-19 Hoffmann La Roche regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
WO2007052055A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
CA2628424A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
DE102005054904A1 (de) * 2005-11-17 2007-05-24 Wacker Polymer Systems Gmbh & Co. Kg Verfahren zur Herstellung polyvinylalkoholstabilisierter Latices
KR20080074143A (ko) 2005-11-29 2008-08-12 노파르티스 아게 퀴놀리논 제제
WO2007067968A2 (fr) 2005-12-08 2007-06-14 Novartis Ag Effets d'inhibiteurs de fgfr3 sur la transcription genetique
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP2010530A2 (fr) * 2006-03-23 2009-01-07 Novartis AG Procedes de preparation de composes contenant de l'imidazole
CA2646891A1 (fr) * 2006-03-23 2007-09-27 Novartis Ag Composes de potentialisation immunitaire
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007110776A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
EP2019686B1 (fr) 2006-03-31 2012-07-11 Novartis AG Immunisation mucosale et parentérale combinée contre le vih
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
MX2008013430A (es) 2006-04-19 2009-01-26 Novartis Vaccines & Diagnostic Compuestos de indazol y metodos para la inhibición de cdc7.
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
US8080563B2 (en) 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (fr) 2006-08-16 2013-08-14 Novartis AG Immunogènes d'Escherischia coli pathogènes des voies urinaires
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
UA101611C2 (ru) * 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
EP2481735A1 (fr) * 2007-05-09 2012-08-01 Pfizer Inc. Dérivés hétérocycliques substitués et leur utilisation pharmaceutique et compositions
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
WO2010100632A2 (fr) 2009-03-06 2010-09-10 Novartis Ag Antigènes de chlamydia
EP2419129A2 (fr) 2009-04-14 2012-02-22 Novartis AG Compositions pour l'immunisation contre staphylococcus aureus
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
JO2860B1 (en) 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
EP4183412B1 (fr) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Compositions à base de protéine f du vrs et procédés de fabrication associés
CA2768343A1 (fr) 2009-07-16 2011-01-20 Novartis Ag Immunogenes d'escherichia coli detoxifies
JPWO2011033588A1 (ja) * 2009-09-18 2013-02-07 株式会社アドバンテスト 試験装置および試験方法
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20120258940A1 (en) 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
EP2519265B1 (fr) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
US8741903B2 (en) 2010-04-16 2014-06-03 Novartis Ag Organic compound for use in the treatment of hepatocellular cancer (HCC)
WO2011128405A1 (fr) 2010-04-16 2011-10-20 Novartis Ag Combinaison de composés organiques
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP6039559B2 (ja) 2010-09-02 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体
JO3062B1 (ar) 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
EP2661435B1 (fr) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
WO2012104776A1 (fr) 2011-01-31 2012-08-09 Novartis Ag Dérivés hétérocycliques inédits
US20130345234A1 (en) 2011-03-17 2013-12-26 Humphrey Athelstan Roy Gardner Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
US20150182525A1 (en) 2011-05-19 2015-07-02 Novartis Ag 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma
EP2554662A1 (fr) 2011-08-05 2013-02-06 M Maria Pia Cosma Procédés pour le traitement de maladies rétiniennes dégénératives
JP2014526506A (ja) 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
MX2014009303A (es) 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
WO2014058785A1 (fr) 2012-10-10 2014-04-17 Novartis Ag Polythérapie
CN103804353A (zh) * 2012-11-01 2014-05-21 常辉 一类治疗精神分裂症的化合物及其用途
CN105142666A (zh) 2012-11-30 2015-12-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2014191938A1 (fr) 2013-05-31 2014-12-04 Novartis Ag Polythérapie comprenant un inhibiteur pi3k-alpha et un inhibiteur de kinase fgfr pour traiter le cancer
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP2870974A1 (fr) 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (fr) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
WO2015155738A2 (fr) 2014-04-09 2015-10-15 Christopher Rudd Utilisation d'inhibiteurs ou d'activateurs de gsk -3 qui modulent l'expression de pd -1 ou de t-bet pour moduler l'immunité due aux lymphocytes t
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2016005752A1 (fr) 2014-07-09 2016-01-14 Tc Biopharm Ltd Lymphocytes t gamma delta et leurs utilisations
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
KR101693781B1 (ko) * 2014-10-06 2017-01-09 한양대학교 에리카산학협력단 다이플루오로알킬기가 도입된 방향족 화합물의 제조 방법
WO2016055916A1 (fr) 2014-10-06 2016-04-14 Novartis Ag Combinaison thérapeutique pour le traitement du cancer
CN104725431B (zh) * 2015-03-19 2017-05-17 广西师范大学 喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用
CN104817535A (zh) * 2015-03-19 2015-08-05 广西师范大学 一种喹啉酮衍生物及其合成方法及应用
CN104774221B (zh) * 2015-03-19 2017-02-08 广西师范大学 喹啉酮衍生物的金属配合物及其合成方法及应用
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
EP3333157B1 (fr) 2015-08-07 2020-12-23 Harbin Zhenbao Pharmaceutical Co., Ltd. Composés vinyliques utilisés comme inhibiteurs du fgfr et du vegfr
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
EP3231434A1 (fr) 2016-04-14 2017-10-18 Fundacio Centre de Regulacio Genomica Procédé de traitement de la maladie de parkinson
WO2018048750A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
EP3509421A4 (fr) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
CN107935858B (zh) * 2016-10-12 2020-09-08 利尔化学股份有限公司 5-氟-2-硝基苯酚的制备方法
EP3645526B1 (fr) 2017-06-27 2024-09-04 Janssen Pharmaceutica NV Nouveaux composés de quinoléinone
BR112020010012A2 (pt) 2017-11-24 2020-10-13 Janssen Pharmaceutica Nv compostos de pirazolopiridinona
AU2018370904B2 (en) 2017-11-24 2023-09-21 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds
US11078194B2 (en) 2017-12-07 2021-08-03 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
CN109553534A (zh) * 2018-11-27 2019-04-02 常州大学 一种2-硝基-4-甲氧基苯甲酸的制备方法
US12398155B2 (en) 2018-12-26 2025-08-26 Janssen Pharmaceutica Nv Thienopyridinone compounds
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
AU2021244786A1 (en) 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2025085233A1 (fr) * 2023-10-20 2025-04-24 Ensem Therapeutics, Inc. Nouveaux dérivés de quinolinones, compositions et méthodes associées

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE236459C (fr)
US158224A (en) * 1874-12-29 Improvement in eye-cups
US207883A (en) * 1878-09-10 Improvement in drafting-pencils
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH07121937B2 (ja) * 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
CA1300918C (fr) * 1987-06-12 1992-05-19 Masataka Kamitani Tuile en ciment arme de fibres et methode de fabrication de ladite tuile
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
EP1306095A3 (fr) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Méthodes et compositions pour cibler les vaisceaux des tumeurs solides
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
WO1995018801A1 (fr) 1994-01-08 1995-07-13 Rhone-Poulenc Agriculture Ltd. Derives de quinoline-3-carboxylate benzimidazoyle, leurs intermediaires ainsi que leur utilisation en tant qu'herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0888310B1 (fr) 1996-03-15 2005-09-07 AstraZeneca AB Derives de cinnoline et leur emploi comme medicaments
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (fr) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Composes azabicycliques substitues et leur utilisation en tant qu'inhibiteurs de la production de tnf et de la photodiesterase cyclique d'amp
IL127559A0 (en) 1996-06-20 1999-10-28 Univ Texas Compounds and methods for providing pharmacologically active preparations and uses thereof
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
PL343112A1 (en) 1998-03-31 2001-07-30 Warner Lambert Co Quinolones as serine protease inhibitors
CA2328893A1 (fr) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
WO2000000481A1 (fr) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
US6174912B1 (en) * 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
WO2000020400A1 (fr) * 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Nouveaux composes et compositions pour le traitement de l'hepatite c
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
KR100373203B1 (ko) * 1999-03-31 2003-02-25 주식회사 엘지화학 새로운 큐마린계 착물 및 이를 이용한 유기 발광 소자
IL144977A0 (en) 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
JP2003171280A (ja) 1999-06-07 2003-06-17 Fujisawa Pharmaceut Co Ltd 抗腫瘍効果増強剤
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
KR100298572B1 (ko) * 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
WO2001029025A2 (fr) 1999-10-19 2001-04-26 Merck & Co., Inc. Inhibiteurs de tyrosine kinases
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001052875A1 (fr) 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Inhibiteur peptidomimetique de vegf-d/vegf-c/vegf
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU2925401A (en) 2000-01-19 2001-07-31 Parkash S Gill Methods and compositions for antisense vegf oligonucleotides
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2004501070A (ja) 2000-03-31 2004-01-15 イムクローン　システムズ　インコーポレイティド 血管内皮成長因子受容体アンタゴニストによる非固形哺乳類腫瘍の処理
JP4341949B2 (ja) * 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
WO2002020500A2 (fr) * 2000-09-01 2002-03-14 Icos Corporation Substances potentialisant un traitement anticancereux et methodes a cet effet
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
MXPA03002601A (es) 2000-09-26 2005-02-25 Univ Arizona Foundation Compuestos y metodos de uso de los mismos en el tratamiento del cancer o de infecciones virales.
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
JP4383870B2 (ja) 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP2573079A3 (fr) 2002-08-23 2015-03-11 Novartis AG Dérivés de benzimidazoles quinolinones et leurs utilisations
EP1545529A4 (fr) 2002-09-30 2010-03-03 Bristol Myers Squibb Co Inhibiteurs de tyrosine kinase
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
EP1581539A4 (fr) 2003-01-03 2007-09-19 Bristol Myers Squibb Co Nouveaux inhibiteurs de tyrosine kinase
AU2003263586A1 (en) 2003-01-09 2004-08-10 University Of Delhi A process for the synthesis of bisbenzimidazoles and its derivations
WO2004087153A2 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de petites molecules de composes pour une immunopotentialisation
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
WO2005053692A1 (fr) 2003-12-01 2005-06-16 The Scripps Research Institute Inhibiteurs de proteines kinases a base de quinolinone perfectionnes
EP1718306A2 (fr) 2004-02-20 2006-11-08 Chiron Corporation Modulation de processus inflammatoires et metastatiques
DK1845990T3 (da) 2005-01-27 2012-01-02 Novartis Vaccines & Diagnostic Behandling af metastaserede tumorer

Also Published As

Publication number Publication date
IL200606A (en) 2010-12-30
US7335774B2 (en) 2008-02-26
WO2002022598A1 (fr) 2002-03-21
NO324155B1 (no) 2007-09-03
US20050209456A1 (en) 2005-09-22
ES2250480T3 (es) 2006-04-16
EP1849782A1 (fr) 2007-10-31
PL211125B1 (pl) 2012-04-30
CA2421120A1 (fr) 2002-03-21
BRPI0113757B8 (pt) 2017-11-07
JP5649672B2 (ja) 2015-01-07
PT1650203E (pt) 2008-05-13
ECSP034548A (es) 2003-05-26
JP2004509112A (ja) 2004-03-25
KR20060036494A (ko) 2006-04-28
DK1317442T3 (da) 2006-02-13
US20020107392A1 (en) 2002-08-08
AU9327501A (en) 2002-03-26
CY1108070T1 (el) 2014-02-12
DZ3425A1 (fr) 2002-03-21
US20050054672A1 (en) 2005-03-10
BRPI0113757B1 (pt) 2017-05-23
DE60132937D1 (de) 2008-04-03
KR100732206B1 (ko) 2007-06-27
EA200300354A1 (ru) 2003-10-30
CY1108931T1 (el) 2014-07-02
AU2001293275B2 (en) 2005-04-14
US20040006101A1 (en) 2004-01-08
EP1317442A1 (fr) 2003-06-11
DE60115069D1 (en) 2005-12-22
EA006711B1 (ru) 2006-02-24
SK2722003A3 (en) 2003-11-04
NO20031097L (no) 2003-03-25
JP4361727B2 (ja) 2009-11-11
DE60132937T2 (de) 2009-02-12
ZA200301578B (en) 2004-08-26
US7598268B2 (en) 2009-10-06
EP1317442B1 (fr) 2005-11-16
SG129306A1 (en) 2007-02-26
ATE386736T1 (de) 2008-03-15
BR0113757A (pt) 2004-03-02
CA2421120C (fr) 2008-07-15
SK287181B6 (sk) 2010-02-08
KR20060101559A (ko) 2006-09-25
MXPA03002032A (es) 2003-07-24
KR100728797B1 (ko) 2007-06-19
US6762194B2 (en) 2004-07-13
PL361698A1 (en) 2004-10-04
IL154618A0 (en) 2003-09-17
NO20031097D0 (no) 2003-03-10
CN1483028A (zh) 2004-03-17
IL154618A (en) 2010-04-29
BG107709A (bg) 2004-01-30
UA75086C2 (en) 2006-03-15
HK1064368A1 (zh) 2005-01-28
DK1650203T3 (da) 2008-06-02
KR100765841B1 (ko) 2007-10-10
NO20071888L (no) 2003-03-25
JP2013100340A (ja) 2013-05-23
US6605617B2 (en) 2003-08-12
JP2007191486A (ja) 2007-08-02
AP1666A (en) 2006-09-29
US6774237B2 (en) 2004-08-10
KR20030029974A (ko) 2003-04-16
EP1650203A1 (fr) 2006-04-26
EP1650203B1 (fr) 2008-02-20
US20030158224A1 (en) 2003-08-21
CN100351249C (zh) 2007-11-28
US6800760B2 (en) 2004-10-05
AP2003002781A0 (en) 2003-06-30
NZ524717A (en) 2004-09-24
HK1053644A1 (en) 2003-10-31
SG174632A1 (en) 2011-10-28
OA12428A (en) 2006-04-19
WO2002022598A8 (fr) 2002-11-21
DE60115069T2 (de) 2006-08-03
US20040097545A1 (en) 2004-05-20
ES2302106T3 (es) 2008-07-01
HU230787B1 (en) 2018-05-02
HUP0301045A2 (hu) 2003-12-29
CZ304344B6 (cs) 2014-03-19
BG66087B1 (bg) 2011-03-31
CZ2003683A3 (cs) 2003-08-13
JP2014129378A (ja) 2014-07-10
NO328723B1 (no) 2010-05-03
ATE309996T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
MA65277B1 (fr) Inhibiteurs de l'inflammasome nlrp3
MA59968B1 (fr) Composés de cyclobutyle dihydroquinoléine sulfonamide
TN2009000138A1 (fr) Biaryl-ether-urees
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
CA2421120A1 (fr) Derives de quinolinone utilises comme inhibiteurs de la tyrosine kinase
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN05165A1 (fr) Derives de pyrrolopyrimidine
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
FR2708605A1 (fr) Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
FR2708608A1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA27808A1 (fr) Derives de quinoleine utilises en tant qu'inhibiteurs de la phosphodiesterase
DE3872029T2 (de) Rektal absorbierbare form von l-dopa.
EP1566379A4 (fr) DERIVES DE QUINOLINE ET DE QUINAZOLINE INHIBANT L'AUTOPHOSPHORYLATION DE Flt3 ET COMPOSITIONS MEDICALES LES CONTENANT
FR2708606A1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
TNSN96161A1 (fr) Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.
EP1175208A4 (fr) Composition de prevention ou de traitement de la demence contenant un derive d'acide hydroxycinnamique ou un extrait d'une plante de l'espece angelicae contenant ledit acide
MA27129A1 (fr) Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine.
FR2608045A1 (fr) Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique